Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein
- PMID: 1717033
- DOI: 10.1111/j.1440-1746.1991.tb01475.x
Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein
Abstract
Earlier studies have reported that interstitial oedematous pancreatitis characterized by hyperamylasaemia can be seen during the early stage of stimulation of supramaximal dose of caerulein. The present study investigated the changes in both cellular and lysosomal fragility and the protective effects of a synthetic protease inhibitor gabexate mesilate (FOY) on this non-invasive model of experimental pancreatitis. The infusion of FOY (50 mg/kg/h) prevented the caerulein-induced increase in serum amylase and pancreatic oedema formation and reduced the elevated amylase content significantly. The administration of FOY with caerulein also reduced the increased lactic dehydrogenase (LDH) discharge significantly and inhibited the cathepsin B leakage from lysosomes in an in vitro incubation system. These results indicate that FOY plays its protective role at the subcellular level--that is, in lysosomes by inhibiting some proteases such as phospholipase A2. The importance of esterases in the pathogenesis of acute pancreatitis is demonstrated. This type of esterase inhibitor may be valuable clinically in the treatment of acute pancreatitis and these results also suggest the role of lysosomal fragility in the pathogenesis of progression of acute pancreatitis.
Similar articles
-
Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007.Pharmacology. 1992;45(2):107-16. doi: 10.1159/000138986. Pharmacology. 1992. PMID: 1381836
-
Protective effects of gabexate mesilate (FOY) against impaired pancreatic energy metabolism in rat acute pancreatitis induced by caerulein.Life Sci. 1991;49(22):PL179-84. doi: 10.1016/0024-3205(91)90063-h. Life Sci. 1991. PMID: 1719326
-
Protective effects of gabexate mesilate on acute pancreatitis induced by tacrolimus (FK-506) in rats in which the pancreas was stimulated by caerulein.J Gastroenterol. 1994 Jun;29(3):305-13. doi: 10.1007/BF02358370. J Gastroenterol. 1994. PMID: 7520321
-
Frank Brooks memorial Lecture: The early intraacinar cell events which occur during acute pancreatitis.Pancreas. 1998 Jul;17(1):31-7. doi: 10.1159/000026152. Pancreas. 1998. PMID: 9667517 Review. No abstract available.
-
Early events in acute pancreatitis.Baillieres Best Pract Res Clin Gastroenterol. 1999 Jul;13(2):213-25. doi: 10.1053/bega.1999.0020. Baillieres Best Pract Res Clin Gastroenterol. 1999. PMID: 11030602 Review.
Cited by
-
Intracellular action of an exogenous low-molecular-weight synthetic protease inhibitor, E3123, in cerulein-induced acute pancreatitis in rats.Int J Pancreatol. 1994 Apr;15(2):119-27. doi: 10.1007/BF02924662. Int J Pancreatol. 1994. PMID: 8071570
-
High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial.J Gastroenterol. 1994 Aug;29(4):479-85. doi: 10.1007/BF02361247. J Gastroenterol. 1994. PMID: 7524945 Clinical Trial.
-
Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.Drugs. 2003;63(17):1799-812. doi: 10.2165/00003495-200363170-00003. Drugs. 2003. PMID: 12921486 Review.
-
Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis.J Gastroenterol. 1996 Oct;31(5):702-9. doi: 10.1007/BF02347620. J Gastroenterol. 1996. PMID: 8887038 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical